3M Oral Rinse Evaluation of Incidence and Patient Acceptance of Sloughing When Used With Sodium Lauryl Sulfate (SLS) Toothpastes
Phase: NA
Conditions: Oral Mucosal Disorder
Sponsor: Solventum US LLC

 
Study Title:        3M Oral Rinse incidence and patient acceptance of sloughing 
when used with Sodium Lauryl Sulfate (SLS) toothpastes 
 
NCT Number:    NCT04601103 
 
Issue Date:          01/07/2020  

Health Care
3M Center
St. Paul, MN 55144-1000
Page 5 of 27
Status: Release
Version: 2
Issue Date: 01/07/2020 08:29:11 AM CST
and reduces the development of the gingivitis associated with dental plaque. Because the rinse acts as
a physical barrier, the FDA classifies the rinse as a Class II Medical Device that requires clinical data
for approval to sell the product.
A past study,
evaluated the efficacy of 3M Oral Rinse on plaque and gingivitis in 200
healthy dental patients that were randomized into 1 of 4 treatment arms. Each treatment arm
contained 50 subjects, randomized to 3M Oral Rinse, 3M vehicle control, predicate device, or water
control. Participants were asked to use an assigned toothpaste and randomly assigned oral rinse for a
period of 6 months. The study found that 3M Oral Rinse reduced plaque and gingivitis and that the
3M Oral Rinse was not statistically different than the predicate device. There were, however,
statistical differences for adverse events observed, namely sloughing.
The current study will evaluate the incidence of sloughing, and other adverse events, over time with
three levels (high, medium, no) of Sodium Lauryl Sulfate (SLS) containing toothpaste in combination
with the 3M Oral Rinse and to determine the subject acceptance of sloughing and/or other side
effects.
3.0 Study Plan
3.1 Design
This will be a single-blind, randomized, internal, two-period crossover 3M sponsored study
evaluating the incidence of sloughing over time with 3 levels (high, medium, no) of sodium
lauryl sulfate (SLS) toothpaste in combination with the 3M Oral Rinse. In addition, this
study is designed to determine the acceptance of sloughing and other side effects of using the
3M Oral Rinse in combination with the assigned toothpaste.
Each subject will be assigned to use the 3M Oral Rinse and randomized to one of three
toothpaste sequences. Each sequence will consist of using two different fluoride toothpastes
(Toothpaste A, B or C), as shown in the table below. The cumulative duration of dosing with
3M Oral Rinse will be six (6) weeks (two 3-week periods). There will be a wash-out period
of at least one week between each period.

Health Care
3M Center
St. Paul, MN 55144-1000
Page 6 of 27
Status: Release
Version: 2
Issue Date: 01/07/2020 08:29:11 AM CST
Sequence: Period 1 →Washout →Period 2
Period 1 (3 weeks)
Period 2 (3 weeks)
Sequence 1
No SLS (Toothpaste A)
High SLS (Toothpaste C)
Sequence 2
Medium SLS (Toothpaste B)
High SLS (Toothpaste C)
Sequence 3
High SLS (Toothpaste C)
Medium SLS (Toothpaste B)
3.2 Duration
The overall time to conduct the study should be at least 14 weeks, including scheduling time
for recruitment and conduct of the study. Each subject will be required to go through the
study consenting and enrollment process. Individuals who qualify for the study will be
scheduled for future dental examinations and participate in the study for at least 7 weeks.
3.3 Investigator/Facility
3M Clinical Research
4.0 Subjects
4.1 Subject Selection
Subjects may only participate if they meet all study-specific selection criteria and sign a
study-specific informed consent form. Exclusion criteria numbers 21 through 27 must be
confirmed by the Screening Dental Exam by the Dental Examiner.
4.2 Inclusion Criteria:
1. Able to understand and willing to sign the informed consent;
2. Willing to agree to maintain confidentiality of the study and study materials;
3. 3M employee aged 18 years and older;
4. Willing to return to the study facility for scheduled study visits and recalls;
5. Agree not to use other oral hygiene products (non-study toothpaste, non-study toothbrush,
mouth rinse, chewing gum);
6. Agree to the study instruction and schedule.
4.3 Exclusion Criteria:
7. A member of the
staff or
product team for the
device under investigation;
8. Have a dental appointment scheduled during study duration for professional cleaning;
9. Is pregnant, nursing, or planning to become pregnant within the study duration;

Health Care
3M Center
St. Paul, MN 55144-1000
Page 7 of 27
Status: Release
Version: 2
Issue Date: 01/07/2020 08:29:11 AM CST
10. History of antibiotic therapy within the previous 30 days or have a condition that is likely
to need antibiotic treatment over the course of the study (e.g., cardiac conditions requiring
antibiotic prophylaxis such as heart murmurs, pacemakers, or prosthetic heart valves and
prosthetic implants);
11. History of using a prescription antimicrobial mouth rinse during the past 3 months;
12. Currently taking medications which may alter gingival appearance/bleeding;
13. Currently using anticonvulsants, calcium channel blockers, or other medications with side
effects known to impact oral health;
14. Participation in any other clinical study within the last 30 days;
15. Resides in the same household with a subject already enrolled in the study;
16. Known history of sensitivity to oral hygiene products;
17. Currently using tobacco products (cigarettes, chewing tobacco) or vaping products (e-
cigarettes);
18. History of diabetes;
19. Have removable partial/full dentures;
20. Have orthodontic appliances;
21. Have medical or oral conditions that may compromise the subject’s safety or interfere
with the conduct and outcome of the study;
22. Have known sloughing within the last 3 weeks;
23. Have dry mouth;
24. Have widespread caries or chronic neglect;
25. Have gross pathological changes of oral soft tissues;
26. Have advanced periodontal disease (purulent exudate, tooth mobility, and/or extensive
alveolar bone loss);
27. Unsuitable for enrollment in this study based on the professional opinion of the dental
examiner based on the oral exam or other reasons not specified in the protocol.
4.4 Subject Recruitment, Screening, Consent
The
staff will recruit subjects using a confidential database
containing
names of
o be listed in the database. Potential subjects
will be contacted once via e-mail to explain the purpose of the study, study requirements,
including inclusion/exclusion criteria, restrictions on activities, information regarding who to
contact for more information and the dates the study will run. The e-mail will include a copy

Health Care
3M Center
St. Paul, MN 55144-1000
Page 8 of 27
Status: Release
Version: 2
Issue Date: 01/07/2020 08:29:11 AM CST
of the informed consent form for the subjects to review. See Appendix I for example
recruitment letter. If the subject agrees to participate, an appointment is scheduled. If any
additional measures, such as advertising, become necessary, they will be submitted to the
IRB prior to their initial use.
4.5 Subject Restrictions
Emergency treatment for a broken tooth, lost filling, or crown is permitted during the study,
at the discretion of the Investigator.
Subjects that need to be withdrawn from treatment during Period 1 are allowed to enter
washout early and complete a longer washout until Period 2.
4.6 Subject Withdrawal
Subjects may voluntarily withdraw from the study at any time without prejudice.
Any subject may be withdrawn by the Investigator from further participation in the study if
the subject:
·
Fails to adhere adequately to the protocol requirements within or outside the clinical
environment
·
Fails to cooperate adequately with the Investigator or staff during clinical visits
·
Presents with an illness or disease condition that is not allowed in the study
·
Experiences a serious AE that requires discontinuation or withdrawal from the study
·
Experiences an intolerable AE
·
Found not to meet the original entry requirements
·
Fails to return for an appointment(s)
·
Is pregnant
If a subject discontinues due to an AE (reported by the subject or the Investigator), the
causative condition will be followed until resolution or stabilization to the Investigator’s
satisfaction.
Withdrawn subjects will not be replaced.
4.7 Confidentiality
All proprietary information relating to 3M investigations and any information obtained during
the study will be regarded as confidential. All study subjects will agree to maintain
confidentiality of proprietary information relating to the investigation and information

Health Care
3M Center
St. Paul, MN 55144-1000
Page 9 of 27
Status: Release
Version: 2
Issue Date: 01/07/2020 08:29:11 AM CST
obtained during the study. In addition, the right of each subject to privacy (confidential
treatment of person data) will be respected at all time. The following safeguards will be
taken to protect that privacy as noted below:
·
All research activities will be conducted in as private a setting as possible.
·
All clinical employees who have access to identifying information are trained in
Good Clinical Practice (GCP) and data privacy.
·
Data, reports, and communications relating to subjects enrolled in the study will
identify each subject only by an assigned subject number. The link between subject
name and subject number is accessible only to study coordinators and other study
staff (investigator, study monitor, clinical manager) as needed for monitoring, subject
payments, etc.
·
The only documents with personal information (informed consent forms and
enrollment log/pay information) are stored in a restricted access documentation
center. Accessible only to a clinical manager and designated clinical employees.
Retention of the documents is subject to applicable state and federal laws and
regulations.
·
The data from this study (and any non-identifying images, including dental
photographs) may be shared within 3M and outside of 3M for future research,
education, publications, presentation, marketing materials, and regulatory
submissions. Subject name or identifying information will not be revealed in any of
these activities or documents.
·
Authorized representative of 3M (study staff, clinical managers, clinical auditors) or
regulatory agencies, such as the US Food and Drug Administration (FDA) and/or
other competent authorities, may examine and copy all study files and therefore may
have access to subject names and identifying information.
5.0 Study Materials
5.1 Description
·
3M Oral Rinse: The principle components of the 3M Oral Rinse being used in
this study are described in Section 1.0 of this document and are the same for all
treatment arms being used in this study. 15mL of 3M Oral Rinse will be swished
for about 30 seconds twice a day (morning and evening), after brushing teeth
with assigned toothpaste, for each 3-week treatment arm.

Health Care
3M Center
St. Paul, MN 55144-1000
Page 10 of 27
Status: Release
Version: 2
Issue Date: 01/07/2020 08:29:11 AM CST
·
Treatment A consists of a no SLS containing toothpaste. For the study, subjects
randomized to Treatment A will receive 1 tube of Sensodyne ProNamel Fresh
Breath toothpaste. The information on the components of Sensodyne toothpaste
are listed on the packaging and safety data sheet.
·
Treatment B consists of a medium SLS containing toothpaste. For the study,
subjects randomized to Treatment B will receive 1 tube of 3M ESPE Clinpro
Tooth Creme toothpaste. The information on the components of 3M Clinpro
toothpaste are listed on the packaging and safety data sheet.
·
Treatment C consists of a high SLS containing toothpaste. For the study,
subjects randomized to Treatment C will receive 1 tube of Colgate Cavity
Protection toothpaste. The information on the components of Colgate toothpaste
are listed on the packaging and safety data sheet.
Subjects will be randomized to take two treatment products in sequence: either A followed by
C, B followed by C, or C followed by B. Each of the treatments will be used in combination
with the 3M Oral Rinse.
5.2 Safety
A biocompatibility statement for this study prepared on December 1, 2017 documents that it
is safe to use the 3M Oral Rinse product in this limited exposure taste-testing evaluation. In
this statement, the 3M Oral Rinse was determined to be safe for the intended use.
Subjects participating in this
clinical study may face the following risks:
·
Temporary, mild, mouth or tongue sensations such as:
o
Numbness,
o
Mild taste alteration,
·
Mild dry mouth,
·
Mild superficial tissue sloughing.
These risks to the subjects are transient and should resolve over time after stopping usage of
the study device.

Health Care
3M Center
St. Paul, MN 55144-1000
Page 11 of 27
Status: Release
Version: 2
Issue Date: 01/07/2020 08:29:11 AM CST
Risks to the subjects are minimized through appropriate selection of subjects by adherence to
the inclusion/exclusion criteria, adherence to the protocol, and through frequent study dental
examinations by the Dental Examiner. Risks are in the consent form and will be
communicated to the subject.
5.3 Regulatory Status
The 3M Oral Rinse formulation is reflective of formulations described in the FDA's Guidance
for Industry and FDA Staff - Class II Special Controls Document: Oral Rinse to Reduce the
Adhesion of Dental Plaque. According to this FDA Guidance, these experimental oral rinse
formulations are subject to premarket notification procedures per 21 CFR 872.5580. As
indicated in this guidance, the key risks associated with this oral rinse include the following:
·
ineffective plaque reduction,
·
alteration of oral flora,
·
adverse tissue reaction (hard and soft tissue), primarily tissue sloughing,
·
toxicity, and
·
improper use
This study is conducted in compliance with the FDA requirements of 21 CFR 812:
Investigational Device Exemptions.
5.4 Labeling
The clinical study batch of 3M Oral Rinse will be manufactured by 3M. It will have a unique
lot number and be supplied in 500mL bottles, labeled with the following information:
·
Product Name
·
·
·
Lot Number
·
Expiration date
·
Instructions for use
·
Investigational use statement
·
Storage conditions
·
Manufacturer name and location

Health Care
3M Center
St. Paul, MN 55144-1000
Page 13 of 27
Status: Release
Version: 2
Issue Date: 01/07/2020 08:29:11 AM CST
•
3M email system (communication with IRB personnel, study subjects, Study
Coordinator(s)/Study Monitor, data management personnel, and, possibly,
team
members.)
6.0 Procedures
6.1 Subject Preparation
Once the subjects have enrolled in the study, subjects will be scheduled for future visits at the
. In order to minimize bias, study subjects will be
asked to refrain from discussing any details about the 3M Oral Rinse study with any other
subjects.
6.2 Schedule of evaluations
Procedure
Visit 1
Period 1
Baseline
Visit 2
Period 1
Mid-
Treatment
Evaluation
Visit 3a
Period 1
End of
Treatment
Visit 4
Period 2
Baseline
Visit 5
Period 2
Mid-
Treatment
Evaluation
Visit 6
Period 2
End of
Treatment/
End of
Study
Day 0
Day 10
(±2 day)
Day 21
(±2 day)
Day 28+
(±2 day)
Day 38+
(±2 day)
Day 49+
(±2 day)
Informed
Consent
X
Eligibility
X
Demographics
X
Dental Exam
X
X
X
X
X
X
Dental
Photographs
Xb
Xb
Xb
Xb
Xb
Randomization
X
Dispense 3M
Oral Rinse
X
X
Dispense
Toothpaste
X
X
Dispense Diary
X
X
Questionnaire
X
X
Assess AEs
X
X
X
X
X
Diary collection
X
X
3M Oral Rinse
collection
X
X
a All subjects will complete a minimum of 1-week wash out with Treatment A between Visits 3 and 4.
b Dental photographs are taken at the discretion of the Dental Examiner to capture sloughing and/or other abnormalities.
6.3 Test Procedures
6.3.1
Visit 1: Period 1 Baseline (Day 0)
·
Subjects will report to the
facility for study baseline procedures
·
Study Coordinator will complete the consenting process

Health Care
3M Center
St. Paul, MN 55144-1000
Page 14 of 27
Status: Release
Version: 2
Issue Date: 01/07/2020 08:29:11 AM CST
·
Study Coordinator and Dental Examiner will review inclusion and
exclusion criteria
·
The Dental Examiner will complete a dental examination
·
Study Coordinator will randomize the subject to their treatment group
and dispense the assigned toothpaste, 3M Oral Rinse, and subject diary
·
Study Coordinator will collect demographic information
·
Study Coordinator will provide verbal and written product use and
subject diary instructions
·
Subjects will initiate their treatment in the evening of baseline visit
·
Study Coordinator will provide subject payment for the visit(s) and all
follow-up visits at the Study Coordinator’s discretion
·
Study Coordinator will schedule follow-up visit(s)
6.3.2
Visit 2: Period 1 Mid-Treatment Evaluation (Day 10)
·
Subjects will report to the
facility for study procedures
·
Dental Examiner will complete a dental examination and record any
AEs, as required
·
Dental photographs may be taken by study staff if oral tissue sloughing
or irritation are found at the dental exam of the affected areas
·
Study Coordinator will schedule follow-up visit(s)
6.3.3
Visit 3: Period 1 End of Treatment (Day 21)
·
Subjects will report to the
facility for study procedures
·
Subjects will return completed subject diaries, study toothpaste tubes,
and 3M Oral Rinse bottles.
·
Dental Examiner will complete a dental examination, review subject
diary, and record any AEs, as required
·
Dental photographs may be taken by study staff if oral tissue sloughing
or irritation are found at the dental exam of the affected areas
·
Subjects will complete the questionnaire
·
Study Coordinator will dispense the assigned toothpaste for at least a 1-
week washout
·
Study Coordinator will schedule follow-up visit(s)

Health Care
3M Center
St. Paul, MN 55144-1000
Page 15 of 27
Status: Release
Version: 2
Issue Date: 01/07/2020 08:29:11 AM CST
6.3.4
Visit 4: Period 2 Baseline (Day 28+)
·
Subjects will report to the
for study procedures
·
Subjects will return study toothpaste tubes used in washout
·
Dental Examiner will complete a dental examination and record any
AEs, as required
·
Dental photographs may be taken by study staff if oral tissue sloughing
or irritation are found at the dental exam of the affected areas
·
Study Coordinator will dispense the assigned toothpaste, 3M Oral Rinse,
and subject diary
·
Study Coordinator will provide verbal and written product use and
subject diary instructions, as needed
·
Subjects will initiate their treatment in the evening of baseline visit
·
Study Coordinator will schedule follow-up visit(s)
6.3.5
Visit 5: Period 2 Mid-Treatment (Day 38+)
·
Subjects will report to the
for study procedures
·
Dental Examiner will complete a dental examination, review subject
diary and record any AEs, as required
·
Dental photographs may be taken by study staff if oral tissue sloughing
or irritation are found at the dental exam of the affected areas
·
Study Coordinator will schedule follow-up visit(s)
6.3.6
Visit 6: Period 2 End of Treatment / End of Study (Day 49+)
·
Subjects will report to the
for study procedures
·
Subjects will return completed subject diaries, study toothpaste tubes and
3M Oral Rinse bottles.
·
Dental Examiner will complete a dental examination, review subject
diary and record any AEs, as required
·
Dental photographs may be taken by study staff if oral tissue sloughing
or irritation are found at the dental exam of the affected areas
·
Subjects will complete the questionnaire

Health Care
3M Center
St. Paul, MN 55144-1000
Page 16 of 27
Status: Release
Version: 2
Issue Date: 01/07/2020 08:29:11 AM CST
6.4 Assessments
6.4.1
Dental Exam
All dental examinations will be completed by the Dental Examiner. The dental
examinations will be documented on study CRFs. The dental examination will
include a visual sloughing evaluation divided into 12 assessment areas: dorsal
surface of the tongue, ventral surface of the tongue, floor of the mouth, roof of
the mouth, right buccal mucosa, gingival tissue (upper right, upper anterior,
upper left), left buccal mucosa, gingival tissue (lower left, lower anterior, lower
right). The Dental Examiner will evaluate the severity of sloughing in these
individual locations using the
the Oral Mucosal Sloughing Index1.
6.4.2
Subject Diary
All subjects will record compliance to study toothpaste and 3M Oral Rinse and
any adverse events experienced on the subject diary, as provided on study CRFs.
6.4.3
Subject Questionnaire
All subjects will complete an acceptability questionnaire at the required
timepoints, as provided on study CRFs.
7.0 Adverse Events
According to the FDA Guidance (Guidance for Clinical Investigators, Sponsors, and IRBs, Adverse
Event Reporting to IRBs-Improving Human Subject Protection-2009), an Adverse Event (AE) can be
any unfavorable and/or unintended sign, symptom, or disease temporally associated with the use of an
investigational product, whether or not it’s related to the investigational product.
AEs can range from anticipated to unanticipated and from mild to serious in nature. Any AE
observed during the conduct of a study should be tracked on the AE CRFs, even if they are
anticipated and mild. However, while we track these events/side effects, most of these occurrences do
not meet the criteria for IRB notification.
Of greater concern are those AEs considered to be unexpected and/or serious in nature and could have
implications for human safety. A serious adverse event is defined as any untoward medical or dental
occurrence that, at any dose: 1) results in death, 2) is life-threatening, 3) requires inpatient

Health Care
3M Center
St. Paul, MN 55144-1000
Page 17 of 27
Status: Release
Version: 2
Issue Date: 01/07/2020 08:29:11 AM CST
hospitalization, 4) results in persistent or significant disability/incapacity, or, 5) in a congenital
anomaly/birth defect. AEs of this nature are required to be reported.
For this study, an adverse event record will be completed and reported to the 3M IRB within 48 hours
for any observation of:
·
Any occurrence of an unanticipated adverse event,
·
Anticipated AEs that occur at a higher frequency or severity that is inconsistent with prior
observations,
·
Any occurrence that results in a medical or dental consultation, or,
·
Any occurrence of a serious adverse event
In addition, an adverse record will be completed and will be included in the final report for the
following anticipated observations of:
·
Temporary, mild, mouth or tongue sensations such as:
o
Numbness,
o
Mild taste alteration,
·
Mild dry mouth,
·
Mild superficial tissue sloughing.
The study Principal Investigator (PI) will monitor all adverse incidents and will triage any subject
who experiences either an unintended and/or serious AE and determine the course of action (i.e. if
they need to be seen by a dental or medical professional). If a dental consultation is necessary the
PI/Study Coordinator will contact the 3M Staff
If medical
care is necessary, the subject will be directed to the
At the subject’s request, they may be referred to another health care professional. In the event of a
research-related injury, compensation will be determined on a case-by-case basis.
A written report of all unanticipated and/or serious AEs will be submitted to the 3M IRB office within
48 hours of the Investigator’s knowledge of the event. The 3M IRB may require additional reports
until the event is resolved. Reports for all Serious Adverse Events (SAEs) and Adverse Device
Reaction (ADRs) will also be forwarded to the
department for FDA

Health Care
3M Center
St. Paul, MN 55144-1000
Page 18 of 27
Status: Release
Version: 2
Issue Date: 01/07/2020 08:29:11 AM CST
notification as appropriate. The final study report will include a comprehensive listing of all AEs;
anticipated, unanticipated, and from mild to serious in nature.
8.0 Randomization
8.1 Randomization
Subjects will be numbered from 01 through 72. This number will be used to identify the
subject on the case report forms. Subjects will be randomized in a 1:1:1 ratio into three
different two-treatment sequences: (1) A-> C (2) B->C and (3) C->B. All seventy-two (72)
subjects will be exposed to the high SLS toothpaste (C), 48 subjects will be exposed to the
medium SLS toothpaste (B), and 24 subjects will be exposed to the no SLS toothpaste (A).
See Appendix II for the randomization schedule.
8.2 Blinding
The Dental Examiner(s) completing the dental examinations will be blinded to the subject
sequence of treatments assigned. The subject, sponsor, and all other study staff will not be
blinded to the treatment sequenced assigned.
9.0 Data Analysis
9.1 Statistical Hypothesis
The main hypothesis under investigation is that the incidence of sloughing over a 3-week
period will be positively correlated with the level of SLS in the toothpaste assigned.
9.2 Sample Size Determination
A sample size of 72 represents a convenient sample size that should yield incidence rate
estimates of adequate precisions to detect gross trends.
A sample size of 24 will give a precision (1/2 confidence interval width) of 4% if the
observed incidence rate is 1%. Likewise, sample size of 48 will give precisions of 8.5-13%
for incidence rates 10-30%, and a sample size of 72 will give precisions of 11.3-11.5% of
incidence rates of 40-50%.
In addition, sample sizes of 72 and 48 will give 74% power to detect differences in
proportions of 50% and 25%, respectively. Furthermore, sample sizes of 48 and 24 will give
77% power to detect differences in 25% and 1%, respectively using a two-sided Fisher’s
exact test with alpha of 0.05.

Health Care
3M Center
St. Paul, MN 55144-1000
Page 19 of 27
Status: Release
Version: 2
Issue Date: 01/07/2020 08:29:11 AM CST
9.3 Populations for Analysis
The datasets that will be used for the primary and secondary analyses including the adverse
event analysis will include all subjects randomized into the study (intent-to-treat population).
There will be no additional subset datasets defined for other analyses or sensitivity analyses.
9.4 Statistical Analyses
9.4.1
Primary Analyses
The primary endpoint is the incidence rate of sloughing. All sloughing clinically
observed or subject-reported over the three-week treatment period will be
recorded as an adverse event and coded using the MedDRA dictionary (with a
preferred term sf oral mucosal exfoliation). Differences in incidence rates will be
tested for significance using a generalized logistic regression model that takes
into account the crossover design with subject as a random effect and treatment,
period, sequence and treatment-by-period interaction as fixed effects, non-
significant treatment-by-period interaction effect will be dropped from the final
model. In the event of failing convergence of the model or finding a significant
treatment-by-period interaction (carry-over effect), the Fisher’s Exact test maybe
used to test for significant differences in sloughing rates among the treatment
arms using all data or Period I data only, respectively.
9.4.2
Secondary Analyses
The 95% confidence intervals will be computed for the sloughing rates for each
treatment group using the Wilson score method. Significant trends in incidence
rates across the treatment groups (from high to medium to no SLS toothpaste)
will be tested using the Cochran Armitage test.
The oral mucosal sloughing index score will be used to compute the following
two outcomes: (a) Overall subject-level incidence based on any non-zero score
among the 12 oral areas examined, and (b) an average subject-level score based
on the mean of 12 severity scores over all oral areas for each subject. These
outcome scores will be summarized for each treatment group and if appropriate,
will be analyzed using a generalized linear regression model such as a Poisson
model to test for significant treatment, period and sequence effects.

Health Care
3M Center
St. Paul, MN 55144-1000
Page 20 of 27
Status: Release
Version: 2
Issue Date: 01/07/2020 08:29:11 AM CST
The diary data will used to compute treatment compliance with expected number
of doses, and this will be summarized per period and treatment group.
Exploratory analysis may occur to examine the onset time and duration of
adverse events.
The data collected on the subject acceptance questionnaire will be summarized
by treatment group. If appropriate, these data will be analyzed for treatment
differences using a generalized linear regression model such as an ordinal
logistical model that takes into account the cross over design and the ordinal
nature of the data.
9.4.3
Adverse Event Analyses
Adverse event data will be coded using the MedDRA dictionary and the
incidence rates will be summarized by preferred term and treatment group.
Differences in incidence rates among the three groups will be tested using an
overall Fisher’s exact test and further pairwise testing (A vs B, A vs C and B vs
C) will be carried out if the overall p-value is significant (<0.05).
9.5 Planned Interim Analysis
There will be no interim analyses for this study.
9.6 Procedures for Missing, Unused, or Spurious Data
Missing data due to subject withdrawals or subjects lost to follow-up will not be imputed. All
data collected from each subject will be used in the statistical analyses.
9.7 Procedures for Reporting Deviations from Statistical Analysis Plan
Any deviations from the statistical analyses outlined in this protocol will be described and
justified in the final study report.
10.0
Personnel Responsibilities
10.1
All Study Staff
Investigator, dental examiners, and staff are required to be current int their
required CITI
training and to comply as stated in
(Preclinical and Clinical Study
Overview),
(
Clinical Studies),
(Biocompatibility Assessment and Testing), and
(Preclinical and
Clinical Documentation Requirements).

Health Care
3M Center
St. Paul, MN 55144-1000
Page 21 of 27
Status: Release
Version: 2
Issue Date: 01/07/2020 08:29:11 AM CST
The Investigator or staff, including the Study Coordinator(s), will review all data entries for
completeness and correctness, and then sign each individual form. All completed CRFs and
copies of subject sign consent forms are to be retained. When changes or corrects are made
on any form, study staff must draw a single line through the error, initial, and date.
10.2
Principal Investigator
The Principal Investigator (PI) has overall responsibility for the welfare of the trial subjects,
design and conduct of the study, ensuring that IRB requirements and applicable regulatory
requirements are met, and that the study site staff has knowledge of their responsibilities as
required for their role in the study. It is the overall responsibility of the PI to ensure that all
study data are complete and accurate and that all study records are placed in the study file.
The PI is responsible for the maintenance of the investigator file and IRB reporting, including
writing the final report.
The PI or designee should maintain a list of appropriately qualified persons to whom
significant study-related duties have been delegated and a signature sheet to document
signatures and initials of all persons authorized to make entries or correction on study CRFs.
10.3
Dental Examiner
The Dental Examiner will be a qualified dental professional, such as a Dentist or Dental
Hygienist. The Dental examiner will complete all dental examination activities, including
dental photographs.
10.4
3M Staff Dentist
Staff Dentist and will have clinical oversight for this study
and complete all dental exam activities, including assessing adverse events.
10.5
Study Staff
The Study Coordinator(s) in the
Clinical Operations Division,
are Laboratory/Technical Specialists who have extensive experience in all aspects of
recruiting, screening, and consenting study subjects.
The Study Coordinator(s) assigned to this project will complete the recruitment of
participants for this project, perform the screening procedures, the consenting process, and
scheduling of all study-related visits/appointments. The Study Coordinator(s) will be

Health Care
3M Center
St. Paul, MN 55144-1000
Page 22 of 27
Status: Release
Version: 2
Issue Date: 01/07/2020 08:29:11 AM CST
responsible for dispensing the study products assigned to each study subject, for providing
and training subjects on subject diaries, and for completing CRFs that will be used at the
assessment visits.
Study Coordinator(s) may be trained to assist the Dental Examiner during dental exams for
activities that do not require a dental professional, such as uploading dental photographs,
cleaning the exam room equipment, and scribing study CRFs.
Study Coordinator(s) will also share responsibilities with the Study Monitor in quality
assurance procedures to ensure the integrity of the study data by assisting with checking the
participants’ responses on the study questionnaires, dental examination forms, study CRFs,
and subject diaries for accuracy and legibility. The Study Coordinator(s) will assist in
generating the final report for this project.
10.6
Study Monitor
The Study Monitor is responsible for ensuring the proper conduct of the study as regards
protocol adherence and validity of the data recorded on the study CRFs. The Study Monitor
will assist the PI and 3M in the maintenance of complete, legible, well-organized, and easily
retrievable data. The Study Monitor will complete all monitoring activities in line with 3M
Standard Operating Procedures (SOPs).
11.0
IRB
Using criteria set forth in Clinical Research Standard Operating Procedure (
Preclinical and Clinical Documentation Requirements), this study is considered to be the type of
study requiring IRB approval before it can be conducted. Information concerning requirements for
Investigational Review Board approval is addressed in Clinical Research Department Standard
Operating Procedures (
).
12.0
Product Disposition
No special inventory is necessary because all materials remain in the control of 3M employees. All
used and unused materials are to be returned to the Investigator.
13.0
Amendment / Deviations
13.1
Amendments
A protocol amendment is defined as a change in procedures that is identified and documented at
any time while conducting the study. All protocol amendments must be documented and

Health Care
3M Center
St. Paul, MN 55144-1000
Page 23 of 27
Status: Release
Version: 2
Issue Date: 01/07/2020 08:29:11 AM CST
approved by the Investigator,
Clinical Study Coordinator, and by the reviewing IRB
prior to being implemented.
13.2
Deviations
A protocol deviation is defined as a change in procedure that has not been documented before
initiation and therefore has not been reviewed and approved with the study sponsor prior to
initiation. All deviations from the study protocol are to be documented and reported to the
investigator and reviewing IRB.
14.0
Monitoring
Monitoring will be completed by the Study Monitor consistent with departmental SOPs and the study
specific Monitoring Plan.
15.0
References
1Green, A., Crichard, S., Ling-Mountford, N., Milward, M., Hubber, N., Gupta, A. K., and Chapple, I.
L. C. (2019). A randomized clinical study comparing the effect of Steareth 30 and SLS
containing toothpastes on oral epithelial integrity (desquamation). Journal of Dentistry,
80(2019), S33-S39.
16.0
Investigator / Sponsor’s Representative Signature
Approval of this document by the IRB representative indicates that the IRB has reviewed and approved
the study submission.
Signer
Role
Date Signed

Health Care
3M Center
St. Paul, MN 55144-1000
Page 24 of 27
Status: Release
Version: 2
Issue Date: 01/07/2020 08:29:11 AM CST
APPENDIX I – Recruitment Letter
3M Oral Rinse incidence and patient acceptance of sloughing when used with Sodium Lauryl
Sulfate (SLS) toothpastes
I am writing to tell you about a research project being conducted here at
The purpose of this study is
to determine the incidence rate of adverse events and acceptance of sloughing and/or other side effects for
an investigative 3M oral care rinse.
The study will involve 6 visits over at least 7 weeks of study participation, including dental exams.
Participation will involve the following:
·
A screening visit to see if you qualify for the study, including providing written consent for
participation.
·
The study procedures will be explained to you and your questions regarding the study will be
answered.
·
If you consent to participate, you will be scheduled for follow-up visits.
·
During study participation, you will be asked to use a 3M Oral Rinse along with provided toothpaste
and to avoid other dental products, such as other rinses, toothpastes, toothbrush, and chewing gum.
·
You will be asked to use the provided oral rinse, tooth paste, and toothbrush for a total of 3 weeks.
·
There will be a follow-up visit with a dental exam in the middle of the 3-week treatment. After 3
weeks, another dental exam will be performed.
·
You will complete a washout with a toothpaste and toothbrush for at least one week. At end of the
washout, you will have a dental exam and be provided with additional oral rinse and a different
toothpaste to use for an additional 3 weeks with similar visits to the first 3-week regimen.
·
You will be asked to complete a questionnaire on your experience using these combined products.
·
You will be asked to complete a daily diary on your experience using these combined products.
You will not receive any personal health benefits as a result of your participation in this research study.

Health Care
3M Center
St. Paul, MN 55144-1000
Page 25 of 27
Status: Release
Version: 2
Issue Date: 01/07/2020 08:29:11 AM CST
Primarily, you will be assisting the
members in understanding people’s acceptance of this
new oral rinse product in conjunction with toothpastes with varying levels of Sodium Lauryl Sulfate (SLS).
The attached consent form contains more specific information. If you are interested in participating in this
study, please respond to this notice with a time that will work from the list below. If you are unable to
participate, please use the voting button at the top of this email message to vote “No Thank You”. If you do
not respond to this email it will be understood that you are not interested in the study and you will not be
contacted again for this study.